ondansetron hydrochloride NDC 83980-017

NDC codes

FDA NDC Directory

Product NDC (as listed)83980-017Labeler and product segments. Claims need a package NDC.

Product NDC at billing width83980-0017Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
83980-017-10	83980001710	1000 TABLET, FILM COATED in 1 BOTTLE (83980-017-10)Marketed from Aug 14, 2026
83980-017-13	83980001713	30 TABLET, FILM COATED in 1 BOTTLE (83980-017-13)Marketed from Aug 14, 2026
83980-017-97	83980001797	10 TABLET, FILM COATED in 1 BOTTLE (83980-017-97)Marketed from Aug 14, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): ondansetron hydrochloride
Generic name (nonproprietary): ondansetron hydrochloride
Active ingredients: Ondansetron hydrochloride — 4 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Ipca Laboratories Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203761
Marketing start: Aug 14, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Serotonin 3 Receptor Antagonists (Mechanism)
Identifiers: Product ID 83980-017_57713a3e-638c-494d-965e-2399c69dd00fSPL ID 57713a3e-638c-494d-965e-2399c69dd00fSPL set ID 7ab3210e-eed1-479a-afc0-f72b5b776883RxCUI 198052, 312086UNII NMH84OZK2BUPC 0383980018136, 0383980017139
Pharmacologic class: Serotonin-3 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N483980001710 followed by a unit qualifier and the quantity

Package 83980-0017-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 22, 2026.

Indications (excerpt from the label)

Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 ) Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 203761

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203761
Product	Strength	Form · route	Labeler	Product NDC
ondansetron hydrochloride	Ondansetron hydrochloride 8 mg/1	Tablet, Film coatedOral	Ipca Laboratories Limited	83980-018